US2016176977A1PendingUtilityA1

Novel acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer

Assignee: AGENSYS INCPriority: Nov 7, 2001Filed: Sep 29, 2014Published: Jun 23, 2016
Est. expiryNov 7, 2021(expired)· nominal 20-yr term from priority
A61P 35/00A61P 37/04C07K 2317/76C07K 14/47C07K 2317/54C12Q 2600/158C07K 2319/30A61K 31/7088A61P 13/10C12Q 1/6886C07K 16/303C07K 16/3023C07K 2317/77C07K 2317/73C07K 16/30C07K 16/40C07K 2317/34A61P 13/08C12N 9/16A61K 51/1045C07K 2317/55C07K 16/3038C07K 16/18C07K 2317/33A61K 2039/505C07K 16/3061C07K 16/3046C07K 16/3069C07K 2317/20G01N 33/5759A61K 40/42A61K 40/24A61K 40/19A61K 2239/38A61K 39/00Y02A50/30
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or antigen binding fragment thereof that immunospecifically binds to an epitope on a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO: 17.

Join the waitlist — get patent alerts

Track US2016176977A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.